chr16-2076173-G-A

Variant names:

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2

The NM_000548.5(TSC2):c.2742+3G>A variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000558 in 1,613,464 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)

Exomes 𝑓: 0.0000055 ( 0 hom. )

Consequence

TSC2
NM_000548.5 splice_region, intron

Scores

Splicing: ADA: 0.00003084

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:4

Conservation

PhyloP100: -0.891

Publications

0 publications found

Variant links:

Genes affected

TSC2 (HGNC:12363): (TSC complex subunit 2) This gene is a tumor suppressor gene that encodes the growth inhibitory protein tuberin. Tuberin interacts with hamartin to form the TSC protein complex which functions in the control of cell growth. This TSC protein complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]

TSC2 Gene-Disease associations (from GenCC):

tuberous sclerosis
Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
tuberous sclerosis 2
Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp, Ambry Genetics
lymphangioleiomyomatosis
Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
tuberous sclerosis complex
Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

TSC2 links:

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP4

Computational evidence support a benign effect (BayesDel_noAF=-0.91).

BP6

Variant 16-2076173-G-A is Benign according to our data. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860. Variant chr16-2076173-G-A is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 535860.

BS2

High AC in GnomAdExome4 at 8 AD gene.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
TSC2	NM_000548.5 link	c.2742+3G>A		splice_region_variant, intron_variant	Intron 24 of 41	ENST00000219476.9	NP_000539.2	P49815-1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
TSC2	ENST00000219476.9 link	c.2742+3G>A		splice_region_variant, intron_variant	Intron 24 of 41	5	NM_000548.5	ENSP00000219476.3		P49815-1

Frequencies

GnomAD3 genomes

AF:

0.00000657

AC:

AN:

152176

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.0000241

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.00

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.00

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.00

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.00

Gnomad OTH

AF:

0.00

GnomAD2 exomes

AF:

0.00000799

AC:

AN:

250260

AF XY:

0.00

show subpopulations

Gnomad AFR exome

AF:

0.000124

Gnomad AMR exome

AF:

0.00

Gnomad ASJ exome

AF:

0.00

Gnomad EAS exome

AF:

0.00

Gnomad FIN exome

AF:

0.00

Gnomad NFE exome

AF:

0.00

Gnomad OTH exome

AF:

0.00

GnomAD4 exome

AF:

0.00000547

AC:

AN:

1461288

Hom.:

Cov.:

AF XY:

0.00000275

AC XY:

AN XY:

726960

show subpopulations

African (AFR)

AF:

0.0000896

AC:

AN:

33478

American (AMR)

AF:

0.00

AC:

AN:

44714

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

26136

East Asian (EAS)

AF:

0.00

AC:

AN:

39700

South Asian (SAS)

AF:

0.00

AC:

AN:

86250

European-Finnish (FIN)

AF:

0.00

AC:

AN:

52866

Middle Eastern (MID)

AF:

0.00

AC:

AN:

5762

European-Non Finnish (NFE)

AF:

0.00000180

AC:

AN:

1111996

Other (OTH)

AF:

0.0000497

AC:

AN:

60386

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.456

Heterozygous variant carriers

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Age Distribution

Exome Het

Variant carriers

<30

30-35

35-40

40-45

45-50

50-55

55-60

60-65

65-70

70-75

75-80

>80

Age

GnomAD4 genome

AF:

0.00000657

AC:

AN:

152176

Hom.:

Cov.:

AF XY:

0.0000135

AC XY:

AN XY:

74332

show subpopulations

African (AFR)

AF:

0.0000241

AC:

AN:

41440

American (AMR)

AF:

0.00

AC:

AN:

15288

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

3472

East Asian (EAS)

AF:

0.00

AC:

AN:

5180

South Asian (SAS)

AF:

0.00

AC:

AN:

4822

European-Finnish (FIN)

AF:

0.00

AC:

AN:

10624

Middle Eastern (MID)

AF:

0.00

AC:

AN:

316

European-Non Finnish (NFE)

AF:

0.00

AC:

AN:

68032

Other (OTH)

AF:

0.00

AC:

AN:

2090

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.475

Heterozygous variant carriers

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Alfa

AF:

0.00

Hom.:

Bravo

AF:

0.0000227

ClinVar

Significance: Conflicting classifications of pathogenicity

Submissions summary: Uncertain:1Benign:4

Revision: criteria provided, conflicting classifications

LINK: link

Submissions by phenotype

Tuberous sclerosis 2

Benign:3

Nov 07, 2021

Genome-Nilou Lab

Significance:Likely benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Sep 09, 2024

Myriad Genetics, Inc.

Significance:Benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This variant is considered benign. This variant is intronic and is not expected to impact mRNA splicing. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. -

Jan 26, 2025

Labcorp Genetics (formerly Invitae), Labcorp

Significance:Benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Tuberous sclerosis syndrome

Uncertain:1

May 12, 2023

Color Diagnostics, LLC DBA Color Health

Significance:Uncertain significance

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This variant causes a G to A nucleotide substitution at the +3 position of intron 24 of the TSC2 gene. To our knowledge, RNA studies have not been reported for this variant. This variant has not been reported in individuals affected with TSC2-related disorders in the literature. This variant has been identified in 2/250260 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -

Hereditary cancer-predisposing syndrome

Benign:1

May 25, 2022

Ambry Genetics

Significance:Likely benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

BayesDel_noAF

Benign

-0.91

CADD

Benign

0.98

(source)

DANN

Benign

0.48

PhyloP100

-0.89

RBP_binding_hub_radar

0.0

RBP_regulation_power_radar

1.0

Mutation Taster

=97/3

polymorphism

(source)

Splicing

Name

Calibrated prediction

Score

Prediction

dbscSNV1_ADA

Benign

0.000031

dbscSNV1_RF

Benign

0.11

SpliceAI score (max)

0.11

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

Publications

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

Age Distribution

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

Other links and lift over